Evidence map›Paper›PMID 29623575›Full record

Observational studyBreast cancer research and treatment2018

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu and 8 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 1 country.

Kun-Ming RauDivision of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Rd, Niaosong Dist., Kaohsiung, 833, Taiwan (ROC).
Fu Ou-YangDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan (ROC).
Ta-Chung ChaoDivision of Medical Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd, Beitou District, Taipei, 11217, Taiwan (ROC).
Yao-Lung KuoDepartment of Surgery, National Cheng-Kung University Hospital, No. 138, Sheng Li Road, Tainan, 704, Taiwan (ROC).
Tsui-Fen ChengBreast Cancer Center, Shin Kong Wu Ho-Su Memorial Hospital, B3, No. 135, Wenchang Rd., Shilin Dist., Taipei, 111, Taiwan (ROC).
Tsu-Yi ChaoDivision of Hematology-Oncology, Taipei Medical University- Shuang Ho Hospital, No. 291, Zhongzheng Rd., Zhonghe District, New Taipei City, 23561, Taiwan (ROC).
Dar-Ren ChenDepartment of Surgery, Changhua Christian Hospital, No. 135, Nanxiao St., Changhua, 500, Taiwan (ROC).
Yen-Dun TzengDivision of General Surgery, Kaohsiung Veterans General Hospital, No. 386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung, 813, Taiwan (ROC).
Being-Whey WangDivision of General Surgery, Kaohsiung Veterans General Hospital, No. 386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung, 813, Taiwan (ROC).
Chun-Yu LiuDivision of Medical Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd, Beitou District, Taipei, 11217, Taiwan (ROC).
Ming-Hung HuDivision of Hematology and Oncology, Cardinal Tien Hospital, No. 362, Zhongzheng Rd., Xindian Dist., New Taipei City, 231, Taiwan (ROC).
Yin-Che LuDivision of Hematology-Oncology, Chia-Yi Christian Hospital, No. 539, Zhongxiao Rd., East Dist., Chiayi, 60002, Taiwan (ROC).
Wei-Jen OuDivision of Medical Oncology, Landseed Hospital, No. 77, Guangtai Rd., Pingzhen Dist., Taoyuan, 324, Taiwan (ROC).
Chin-Ho KuoDivision of Hematology-Oncology, Chia-Yi Christian Hospital, No. 539, Zhongxiao Rd., East Dist., Chiayi, 60002, Taiwan (ROC).
Chieh-Han ChuangDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan (ROC).
Jung-Yu KanDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan (ROC).
Fang-Ming ChenDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan (ROC). fchen@kmu.edu.tw.
Ming-Feng HouDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan (ROC). mifeho@kmu.edu.tw.ORCID http://orcid.org/0000-0001-6030-9702
Kaohsiung Medical University · TWTaipei Veterans General Hospital · TWChia-Yi Christian Hospital · TWKaohsiung Breast Cancer Promotion and Education Society · TWCardinal Tien Hospital · TWChang Gung Memorial Hospital · TWChanghua Christian Hospital · TWKaohsiung Chang Gung Memorial Hospital · TWLandseed Hospital · TWNational Cheng Kung University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer.

methodsThis retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer.

resultsThe survival rate at 24 months was 57.2% (95% CI 51.0-62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45-3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients' tumors with the luminal A subtype had a significantly better objective response rate. Kaplan-Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events.

conclusionsEribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug Administration ScheduleFemaleFuransHumansKaplan-Meier EstimateKetonesMiddle AgedNeoplasm MetastasisNeoplasm StagingPolyether PolyketidesAntineoplastic AgentsBiomarkers, TumoreribulinFuransKetonesPolyether PolyketidesEfficacyEribulinMetastatic breast cancerReal worldSafetyTaiwanese women

Identifiers

PMID29623575
PMCPMC6022524
OpenAlexW2795873743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.